// Auto-generated - do not edit
export const substanceName = "Amobarbital";
export const sources = [{"id":"drugbank","fileName":"DRUGBANK - Amobarbital.md","displayName":"DrugBank","size":16179},{"id":"protestkit","fileName":"PROTESTKIT - Amobarbital.json","displayName":"Protest Kit","size":3717},{"id":"tripsit-factsheets","fileName":"TRIPSIT_FACTSHEETS - Amobarbital.md","displayName":"TripSit Factsheets","size":734},{"id":"wikipedia","fileName":"WIKIPEDIA - Amobarbital.md","displayName":"Wikipedia","size":5902}];
export const contents: Record<string, string> = {
  "drugbank": `# Amobarbital
*Source: https://go.drugbank.com/drugs/DB01351*

## Overview

### Description

This compound belongs to the class of organic compounds known as pyrimidones. These are compounds that contain a pyrimidine ring, which bears a ketone. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.

### Background

A barbiturate with hypnotic and sedative properties (but not antianxiety). Adverse effects are mainly a consequence of dose-related CNS depression and the risk of dependence with continued use is high. (From Martindale, The Extra Pharmacopoeia, 30th ed, p565)

### Mechanism of Action

Gamma-aminobutyric acid receptor subunit alpha-1
Potentiator
Gamma-aminobutyric acid receptor subunit alpha-2
Potentiator
Gamma-aminobutyric acid receptor subunit alpha-3
Potentiator
+ 3 more targets

### Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

1,2-Benzodiazepine
The risk or severity of CNS depression can be increased when Amobarbital is combined with 1,2-Benzodiazepine.
Abaloparatide
Amobarbital may increase the hypotensive activities of Abaloparatide.
Abemaciclib
The metabolism of Abemaciclib can be increased when combined with Amobarbital.
Acalabrutinib
The metabolism of Acalabrutinib can be increased when combined with Amobarbital.
Acebutolol
Amobarbital may increase the hypotensive activities of Acebutolol.

### Food Interactions

Avoid alcohol. Ingesting alcohol may increase the CNS depressant effects of amobarbital.
Take on an empty stomach. Taking oral amobarbital sodium on an empty stomach increases the rate of absorption.

## Chemical Information

**DrugBank ID:** DB01351

**Synonyms:** 5-ethyl-5-(3-methylbutyl)-2,4,6(1H,3H,5H)-pyrimidinetrione
5-ethyl-5-(3-methylbutyl)barbituric acid
5-ethyl-5-isoamylbarbituric acid
5-ethyl-5-isopentylbarbituric acid
Amobarbital
Amobarbitale
Amylobarbitone
Barbamil
Barbamyl

**Chemical Formula:** C
11
H
18
N
2
O
3

**SMILES:** CCC1(CCC(C)C)C(=O)NC(=O)NC1=O

**Weight:** Average: 226.2722
Monoisotopic: 226.131742452

**IUPAC Name:** 5-ethyl-5-(3-methylbutyl)-1,3-diazinane-2,4,6-trione

## Additional Information

### Modality

Small Molecule

### Patents

0

### Indicated Conditions

0

### Phase 0

0

### Phase 1

2

### Phase 2

0

### Phase 3

0

### Phase 4

1

### Summary

Amobarbital
is a barbiturate derivative used for the induction of sedation during procedures, short-term management of insomnia, and acute management of refractory tonic-clonic seizures.

### Generic Name

Amobarbital

### DrugBank Accession Number

DB01351

### Groups

Approved, Illicit, Investigational

### Structure

3D
Download
MOL
SDF
3D-SDF
PDB
SMILES
InChI
Similar Structures
Structure for Amobarbital (DB01351)
×
Close

### Associated Conditions

Indication Type
Indication
Combined Product Details
Approval Level
Age Group
Patient Characteristics
Dose Form
Create Account

### Mechanism of action

Amobarbital (like all barbiturates) works by binding to the GABAA receptor at either the alpha or the beta sub unit.  These are binding sites that are distinct from GABA itself and also distinct from the benzodiazepine binding site. Like benzodiazepines, barbiturates potentiate the effect of GABA at this receptor.  This GABAA receptor binding decreases input resistance, depresses burst and tonic firing, especially in ventrobasal and intralaminar neurons, while at the same time increasing burst duration and mean conductance at individual chloride channels; this increases both the amplitude and decay time of inhibitory postsynaptic currents.  In addition to this GABA-ergic effect, barbiturates also block the AMPA receptor, a subtype of glutamate receptor. Glutamate is the principal excitatory neurotransmitter in the mammalian CNS.  Amobarbital also appears to bind neuronal nicotinic acetylcholine receptors.
Target
Actions
Organism
A
Gamma-aminobutyric acid receptor subunit alpha-1
potentiator
Humans
A
Gamma-aminobutyric acid receptor subunit alpha-2
potentiator
Humans
A
Gamma-aminobutyric acid receptor subunit alpha-3
potentiator
Humans
A
Gamma-aminobutyric acid receptor subunit alpha-4
potentiator
Humans
A
Gamma-aminobutyric acid receptor subunit alpha-5
potentiator
Humans
A
Gamma-aminobutyric acid receptor subunit alpha-6
potentiator
Humans
U
Neuronal acetylcholine receptor subunit alpha-4
antagonist
Humans
U
Neuronal acetylcholine receptor subunit alpha-7
antagonist
Humans
U
Glutamate receptor 2
antagonist
Humans
U
Glutamate receptor ionotropic, kainate 2
antagonist
Humans

### Product Ingredients

Ingredient
UNII
CAS
InChI Key
Amobarbital sodium
G0313KNC7D
64-43-7
BNHGKKNINBGEQL-UHFFFAOYSA-M

### International/Other Brands

Amytal
/
Isomytal

### Brand Name Prescription Products

Name
Dosage
Strength
Route
Labeller
Marketing Start
Marketing End
Region
Image
Amytal Sodium
Injection, powder, lyophilized, for solution
0.5 g/5mL
Intramuscular; Intravenous
Bausch Health, Canada Inc.
2008-09-25
Not applicable
US
Amytal Sodium
Injection, powder, lyophilized, for solution
0.5 g/5mL
Intramuscular; Intravenous
Marathon Pharmaceuticals
2008-09-25
2016-03-31
US

### Mixture Products

Name
Ingredients
Dosage
Route
Labeller
Marketing Start
Marketing End
Region
Image
Tuinal Pulvule 303
Amobarbital sodium
(50 mg)
+
Secobarbital sodium
(50 mg)
Capsule
Oral
Pharmascience Inc
1945-12-31
2004-03-05
Canada
Tuinal Pulvule 304
Amobarbital sodium
(100 mg / cap)
+
Secobarbital sodium
(100 mg / cap)
Capsule
Oral
Pharmascience Inc
1945-12-31
2004-03-05
Canada

### Unapproved/Other Products

Name
Ingredients
Dosage
Route
Labeller
Marketing Start
Marketing End
Region
Image
Amytal Sodium
Amobarbital sodium
(0.5 g/5mL)
Injection, powder, lyophilized, for solution
Intramuscular; Intravenous
Bausch Health, Canada Inc.
2008-09-25
Not applicable
US
Amytal Sodium
Amobarbital sodium
(0.5 g/5mL)
Injection, powder, lyophilized, for solution
Intramuscular; Intravenous
Marathon Pharmaceuticals
2008-09-25
2016-03-31
US

### ATC Codes

N05CA02 — Amobarbital
N05CA — Barbiturates, plain
N05C — HYPNOTICS AND SEDATIVES
N05 — PSYCHOLEPTICS
N — NERVOUS SYSTEM
N05CB01 — Combinations of barbiturates
N05CB — Barbiturates, combinations
N05C — HYPNOTICS AND SEDATIVES
N05 — PSYCHOLEPTICS
N — NERVOUS SYSTEM

### Drug Categories

Anticholinergic Agents
Anticonvulsants
Barbiturates
Barbiturates, Plain
Central Nervous System Agents
Central Nervous System Depressants
Cytochrome P-450 CYP3A Inducers
Cytochrome P-450 CYP3A4 Inducers
Cytochrome P-450 CYP3A4 Inducers (strength unknown)
Cytochrome P-450 Enzyme Inducers
GABA Agents
GABA Modulators
Hypnotics and Sedatives
Nervous System
Neurotransmitter Agents
Nicotinic Antagonists
Psycholeptics
Pyrimidines
Pyrimidinones

### Chemical TaxonomyProvided byClassyfire

Description
This compound belongs to the class of organic compounds known as pyrimidones. These are compounds that contain a pyrimidine ring, which bears a ketone. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazines
Sub Class
Pyrimidines and pyrimidine derivatives
Direct Parent
Pyrimidones
Alternative Parents
Hydropyrimidines
/
Organic carbonic acids and derivatives
/
Propargyl-type 1,3-dipolar organic compounds
/
Azacyclic compounds
/
Organopnictogen compounds
/
Organonitrogen compounds
/
Organic oxides
/
Hydrocarbon derivatives
/
Carbonyl compounds
Substituents
2,5-dihydropyrimidine
/
Aliphatic heteromonocyclic compound
/
Azacycle
/
Carbonic acid derivative
/
Carbonyl group
/
Hydrocarbon derivative
/
Hydropyrimidine
/
Organic 1,3-dipolar compound
/
Organic nitrogen compound
/
Organic oxide
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
barbiturates (
CHEBI:2673
)

### Kingdom

Organic compounds

### Super Class

Organoheterocyclic compounds

### Class

Diazines

### Sub Class

Pyrimidines and pyrimidine derivatives

### Direct Parent

Pyrimidones

### Alternative Parents

Hydropyrimidines
/
Organic carbonic acids and derivatives
/
Propargyl-type 1,3-dipolar organic compounds
/
Azacyclic compounds
/
Organopnictogen compounds
/
Organonitrogen compounds
/
Organic oxides
/
Hydrocarbon derivatives
/
Carbonyl compounds

### Substituents

2,5-dihydropyrimidine
/
Aliphatic heteromonocyclic compound
/
Azacycle
/
Carbonic acid derivative
/
Carbonyl group
/
Hydrocarbon derivative
/
Hydropyrimidine
/
Organic 1,3-dipolar compound
/
Organic nitrogen compound
/
Organic oxide

### Molecular Framework

Aliphatic heteromonocyclic compounds

### External Descriptors

barbiturates (
CHEBI:2673
)

### UNII

GWH6IJ239E

### CAS number

57-43-2

### InChI Key

VIROVYVQCGLCII-UHFFFAOYSA-N

### InChI

InChI=1S/C11H18N2O3/c1-4-11(6-5-7(2)3)8(14)12-10(16)13-9(11)15/h7H,4-6H2,1-3H3,(H2,12,13,14,15,16)

### General References

Kim HS, Wan X, Mathers DA, Puil E: Selective GABA-receptor actions of amobarbital on thalamic neurons. Br J Pharmacol. 2004 Oct;143(4):485-94. Epub 2004 Sep 20. [
Article
]
Maynert EW: The alcoholic metabolites of pentobarbital and amobarbital in man. J Pharmacol Exp Ther. 1965 Oct;150(1):118-21. [
Article
]
Tang BK, Kalow W, Grey AA: Amobarbital metabolism in man: N-glucoside formation. Res Commun Chem Pathol Pharmacol. 1978 Jul;21(1):45-53. [
Article
]
Soine PJ, Soine WH: High-performance liquid chromatographic determination of the diastereomers of 1-(beta-D-glucopyranosyl)amobarbital in urine. J Chromatogr. 1987 Nov 27;422:309-14. [
Article
]
McCall WV: The addition of intravenous caffeine during an amobarbital interview. J Psychiatry Neurosci. 1992 Nov;17(5):195-7. [
Article
]

### External Links

Human Metabolome Database
HMDB0015440
KEGG Drug
D00555
KEGG Compound
C07536
PubChem Compound
2164
PubChem Substance
46508165
ChemSpider
2079
RxNav
719
ChEBI
2673
ChEMBL
CHEMBL267894
ZINC
ZINC000004811698
Therapeutic Targets Database
DAP000686
PharmGKB
PA448401
Wikipedia
Amobarbital

### Human Metabolome Database

HMDB0015440

### KEGG Drug

D00555

### KEGG Compound

C07536

### PubChem Compound

2164

### PubChem Substance

46508165

### ChemSpider

2079

### RxNav

719

### ChEBI

2673

### ChEMBL

CHEMBL267894

### ZINC

ZINC000004811698

### Therapeutic Targets Database

DAP000686

### PharmGKB

PA448401

### Wikipedia

Amobarbital

### Packagers

AAIPharma Inc.
Marathon Pharmaceuticals
Ranbaxy Laboratories

### Dosage Forms

Form
Route
Strength
Injection, powder, lyophilized, for solution
Intramuscular; Intravenous
0.5 g/5mL
Powder, for solution
Intramuscular; Intravenous
500 mg / amp
Capsule
Oral
60 mg / cap
Capsule
Oral
200 mg / cap
Capsule
Oral

### Prices

Unit description
Cost
Unit
Amytal sodium 0.5 gram vial
117.35USD
vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

### State

Solid

### Experimental Properties

Property
Value
Source
melting point (°C)
157 °C
PhysProp
water solubility
603 mg/L (at 25 °C)
YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP
2.07
HANSCH,C ET AL. (1995)
logS
-2.57
ADME Research, USCD
pKa
7.84
SANGSTER (1994)

### Predicted Properties

Property
Value
Source
Water Solubility
0.897 mg/mL
ALOGPS
logP
1.87
ALOGPS
logP
1.89
Chemaxon
logS
-2.4
ALOGPS
pKa (Strongest Acidic)
7.48
Chemaxon
Physiological Charge
0
Chemaxon
Hydrogen Acceptor Count
3
Chemaxon
Hydrogen Donor Count
2
Chemaxon
Polar Surface Area
75.27 Å
2
Chemaxon
Rotatable Bond Count
4
Chemaxon
Refractivity
58 m
3
·mol
-1
Chemaxon
Polarizability
23.45 Å
3
Chemaxon
Number of Rings
1
Chemaxon
Bioavailability
1
Chemaxon
Rule of Five
Yes
Chemaxon
Ghose Filter
Yes
Chemaxon
Veber's Rule
No
Chemaxon
MDDR-like Rule
No
Chemaxon

### Predicted ADMET Features

Property
Value
Probability
Human Intestinal Absorption
+
0.9254
Blood Brain Barrier
+
0.949
Caco-2 permeable
-
0.5913
P-glycoprotein substrate
Substrate
0.6471
P-glycoprotein inhibitor I
Non-inhibitor
0.5906
P-glycoprotein inhibitor II
Non-inhibitor
0.9426
Renal organic cation transporter
Non-inhibitor
0.9307
CYP450 2C9 substrate
Non-substrate
0.7591
CYP450 2D6 substrate
Non-substrate
0.9011
CYP450 3A4 substrate
Non-substrate
0.663
CYP450 1A2 substrate
Non-inhibitor
0.879
CYP450 2C9 inhibitor
Non-inhibitor
0.7603
CYP450 2D6 inhibitor
Non-inhibitor
0.9299
CYP450 2C19 inhibitor
Non-inhibitor
0.7269
CYP450 3A4 inhibitor
Non-inhibitor
0.9422
CYP450 inhibitory promiscuity
Low CYP Inhibitory Promiscuity
0.9105
Ames test
Non AMES toxic
0.691
Carcinogenicity
Non-carcinogens
0.8925
Biodegradation
Not ready biodegradable
0.944
Rat acute toxicity
2.9884 LD50, mol/kg
Not applicable
hERG inhibition (predictor I)
Weak inhibitor
0.9852
hERG inhibition (predictor II)
Non-inhibitor
0.8963
ADMET data is predicted using
admetSAR
, a free tool for evaluating chemical ADMET properties. (
23092397
)

### Mass Spec (NIST)

Download
(8.4 KB)

### Spectra

Spectrum
Spectrum Type
Splash Key
Predicted GC-MS Spectrum - GC-MS
Predicted GC-MS
splash10-0006-9620000000-6298f9a27728bfc9722a
GC-MS Spectrum - CI-B
GC-MS
splash10-004i-0090000000-5962005393da49f25b6d
GC-MS Spectrum - EI-B
GC-MS
splash10-0a4l-3900000000-4b439f0aa2820ea498c7
Mass Spectrum (Electron Ionization)
MS
splash10-0a4l-4900000000-8b443325c415e154ac85
Predicted MS/MS Spectrum - 10V, Positive (Annotated)
Predicted LC-MS/MS
splash10-004i-0590000000-56a8a5a9f4c52ede367a
Predicted MS/MS Spectrum - 10V, Negative (Annotated)
Predicted LC-MS/MS
splash10-004i-2090000000-784c598cba5b353d59e8
Predicted MS/MS Spectrum - 20V, Negative (Annotated)
Predicted LC-MS/MS
splash10-0006-9300000000-4a529f360f5a165ee5c5
Predicted MS/MS Spectrum - 20V, Positive (Annotated)
Predicted LC-MS/MS
splash10-0btc-2910000000-abbb8276eb917aa16d46
Predicted MS/MS Spectrum - 40V, Negative (Annotated)
Predicted LC-MS/MS
splash10-0006-9400000000-b8eace5bc0de34c93490
Predicted MS/MS Spectrum - 40V, Positive (Annotated)
Predicted LC-MS/MS
splash10-0k96-0910000000-3b8c18c9d388e8f4882a
1H NMR Spectrum
1D NMR
Not Applicable
13C NMR Spectrum
1D NMR
Not Applicable
Predicted 1H NMR Spectrum
1D NMR
Not Applicable
Predicted 13C NMR Spectrum
1D NMR
Not Applicable

### Chromatographic Properties

Collision Cross Sections (CCS)
Adduct
CCS Value (Å
2
)
Source type
Source
[M-H]-
159.9447852
predicted
DarkChem Lite v0.1.0
[M-H]-
159.4596852
predicted
DarkChem Lite v0.1.0
[M-H]-
159.2641852
predicted
DarkChem Lite v0.1.0
[M-H]-
148.12143
predicted
DeepCCS 1.0 (2019)
[M+H]+
160.1398852
predicted
DarkChem Lite v0.1.0
[M+H]+
159.9536852
predicted
DarkChem Lite v0.1.0
[M+H]+
160.4163852
predicted
DarkChem Lite v0.1.0
[M+H]+
151.56464
predicted
DeepCCS 1.0 (2019)
[M+Na]+
160.1979852
predicted
DarkChem Lite v0.1.0
[M+Na]+
160.1036852
predicted
DarkChem Lite v0.1.0
[M+Na]+
160.57866
predicted
DeepCCS 1.0 (2019)

### Kind

Protein

### Organism

Humans

### Pharmacological action

Unknown

### Actions

Antagonist

### General Function

Ionotropic glutamate receptor that functions as a cation permeable ligand-gated ion channel, gated by L-glutamate and the glutamatergic agonist kainic acid. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and thereby converts the chemical signal to an electrical impulse. The receptor then desensitizes rapidly and enters a transient inactive state, characterized by the presence of bound agonist (PubMed:14511640, PubMed:28180184, PubMed:34375587, PubMed:7536611, PubMed:8730589). Modulates cell surface expression of NETO2. In association with GRIK3, involved in presynaptic facilitation of glutamate release at hippocampal mossy fiber synapses (By similarity)

### Specific Function

extracellularly glutamate-gated ion channel activity

### Gene Name

GRIK2

### Uniprot ID

Q13002

### Uniprot Name

Glutamate receptor ionotropic, kainate 2

### Molecular Weight

102582.475 Da

`,
  "protestkit": `{
  "url": "https://drugs.tripsit.me/amobarbital",
  "experiencesUrl": "https://www.reddit.com/search/?q=Amobarbital",
  "name": "Amobarbital",
  "aliases": [],
  "aliasesStr": "",
  "summary": "A sedative and hypnotic barbiturate first discovered in 1923. Formerly widely used recreationally and medically, barbiturates have declined in popularity with the appearance of benzodiazepines and other drugs with less serious consequences in overdose.",
  "reagents": null,
  "classes": {
    "chemical": [],
    "psychoactive": []
  },
  "toxicity": null,
  "addictionPotential": null,
  "tolerance": null,
  "crossTolerances": null,
  "roas": [
    {
      "name": "Oral",
      "dosage": [
        {
          "name": "Light",
          "value": "50mg"
        },
        {
          "name": "Common",
          "value": "50-75mg"
        },
        {
          "name": "Strong",
          "value": "75-150mg+"
        }
      ],
      "duration": [
        {
          "name": "Onset",
          "value": "0.17 - 0.5 hours"
        },
        {
          "name": "Duration",
          "value": "5.0 - 9.0 hours"
        },
        {
          "name": "After effects",
          "value": "2.0 - 12.0 hours"
        }
      ],
      "bioavailability": null
    }
  ],
  "interactions": [
    {
      "name": "2C-T-x",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "2C-x",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "5-MeO-xxT",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "Alcohol",
      "status": "Dangerous"
    },
    {
      "name": "Amphetamines",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "Caffeine",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "Cannabis",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "Cocaine",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "DMT",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "DOx",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "DXM",
      "status": "Caution"
    },
    {
      "name": "GHB/GBL",
      "status": "Dangerous"
    },
    {
      "name": "Gabapentinoids",
      "status": "Unsafe"
    },
    {
      "name": "Ketamine",
      "status": "Caution"
    },
    {
      "name": "LSD",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "MAOIs",
      "status": "Low Risk & Synergy"
    },
    {
      "name": "MDMA",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "MMC class",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "MXE",
      "status": "Caution"
    },
    {
      "name": "Mescaline",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "Mushrooms",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "NBOMes",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "Nitrous",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "Opioids",
      "status": "Dangerous"
    },
    {
      "name": "PDA5",
      "status": "Caution"
    },
    {
      "name": "PVP class",
      "status": "Unsafe"
    },
    {
      "name": "Poppers",
      "status": "Unsafe"
    },
    {
      "name": "SSRIs",
      "status": "Low Risk & No Synergy"
    },
    {
      "name": "Tramadol",
      "status": "Dangerous"
    }
  ],
  "effects": "Anxiolytic, Sedative, Muscle Relaxant, Amnesia, Dystaxia, Hypnotic.",
  "categorized_effects": {
    "Physical effects": [
      "Sedative",
      "Muscle Relaxant",
      "Dystaxia"
    ],
    "Mental effects": [
      "Anxiolytic",
      "Amnesia"
    ],
    "Sensory effects": [],
    "Uncategorized effects": [
      "Hypnotic."
    ]
  }
}`,
  "tripsit-factsheets": `# Amobarbital
*Source: TripSit Factsheets (tripsit.me)*

## Summary

A sedative and hypnotic barbiturate first discovered in 1923. Formerly widely used recreationally and medically, barbiturates have declined in popularity with the appearance of benzodiazepines and other drugs with less serious consequences in overdose.

## Classification
- **Categories:** depressant, habit-forming, barbiturate

## Dosage

### Oral
- **Common:** 50-75mg
- **Light:** 50mg
- **Strong:** 75-150mg+

## Duration
- **Onset:** 10-30 minutes
- **Duration:** 5-9 hours
- **After Effects:** 2-12 hours

## Effects
- Anxiolytic
- Sedative
- Muscle Relaxant
- Amnesia
- Dystaxia
- Hypnotic

## Additional Information
- **Avoid:** All other CNS depressants.
`,
  "wikipedia": `# Amobarbital
*Source: https://en.wikipedia.org/wiki/Amobarbital*

Amobarbital (formerly known as amylobarbitone or sodium amytal as the soluble sodium salt) is a drug that is a barbiturate derivative. It has sedative-hypnotic properties. It is a white crystalline powder with no odor and a slightly bitter taste. It was first synthesized in Germany in 1923. It is considered a short to intermediate acting barbiturate.
If amobarbital is taken for extended periods of time, physiological and psychological dependence can develop. Amobarbital withdrawal mimics delirium tremens and may be life-threatening. Amobarbital was manufactured by Eli Lilly and Company in the United States under the brand name Amytal in bright blue bullet shaped capsules (known as Pulvules) or pink tablets (known as Diskets) containing 50, 100, or 200 milligrams of the drug. The drug was also manufactured generically.
Amobarbital was widely misused, known as "Blue Heavens" on the street. Amytal, as well as Tuinal, a combination drug containing equal quantities of secobarbital and amobarbital, were both manufactured by Eli Lilly until the late 1990s. However, as the popularity of benzodiazepines increased, prescriptions for these medications became increasingly rare beginning in the mid to late 1980s.

## Pharmacology

In an in vitro study in rat thalamic slices, amobarbital worked by activating GABAA receptors, which decreased input resistance, depressed burst and tonic firing, especially in ventrobasal and intralaminar neurons, while at the same time increasing burst duration and mean conductance at individual chloride channels; this increased both the amplitude and decay time of inhibitory postsynaptic currents.
Amobarbital has been used in a study to inhibit mitochondrial electron transport in the rat heart in an attempt to preserve mitochondrial function following reperfusion.
A 1988 study found that amobarbital increases benzodiazepine receptor binding in vivo with less potency than secobarbital and pentobarbital (in descending order), but greater than phenobarbital and barbital (in descending order). (Secobarbital > pentobarbital > amobarbital > phenobarbital > barbital)
It has an LD50 in mice of 212 mg/kg s.c.

## Metabolism

Amobarbital undergoes both hydroxylation to form 3'-hydroxyamobarbital, and N-glucosidation to form 1-(beta-D-glucopyranosyl)-amobarbital.

## Indications

### Approved

Anxiety
Epilepsy
Insomnia
Wada test

### Unapproved/off-label

When given slowly by an intravenous route, sodium amobarbital has a reputation for acting as a so-called truth serum. Under the influence, a person will divulge information that under normal circumstances they would block. This was most likely due to loss of inhibition. As such, the drug was first employed clinically by William Bleckwenn at the University of Wisconsin to circumvent inhibitions in psychiatric patients. The use of amobarbital as a truth serum has lost credibility due to the discovery that a subject can be coerced into having a "false memory" of the event.
The drug may be used intravenously to interview patients with catatonic mutism, sometimes combined with caffeine to prevent sleep.
It was used by the United States armed forces during World War II in an attempt to treat shell shock and return soldiers to the front-line duties. This use has since been discontinued as the powerful sedation, cognitive impairment, and dis-coordination induced by the drug greatly reduced soldiers' usefulness in the field.

## Contraindications

The following drugs should be avoided when taking amobarbital:

Antiarrhythmics, such as verapamil and digoxin
Antiepileptics, such as phenobarbital or carbamazepine
Antihistamines, such as doxylamine and clemastine
Antihypertensives, such as atenolol and propranolol
Ethanol
Benzodiazepines, such as diazepam, clonazepam, nitrazepam, alprazolam, or lorazepam
Chloramphenicol
Chlorpromazine
Cyclophosphamide
Ciclosporin
Digitoxin
Doxorubicin
Doxycycline
Methoxyflurane
Metronidazole
Narcotic analgesics, such as morphine and oxycodone
Quinine
Steroids, such as prednisone and cortisone
Theophylline
Warfarin

## Interactions

Amobarbital has been known to decrease the effects of hormonal birth control.

## Overdose

Some side effects of overdose include confusion (severe); decrease in or loss of reflexes; drowsiness (severe); fever; irritability (continuing); low body temperature; poor judgment; shortness of breath or slow or troubled breathing; slow heartbeat; slurred speech; staggering; trouble in sleeping; unusual movements of the eyes; weakness (severe). Severe overdose may result in death without intervention.

## Chemistry

Amobarbital (5-ethyl-5-isoamylbarbituric acid), like all barbiturates, is synthesized by reacting malonic acid derivatives with urea derivatives. In particular, in order to make amobarbital, α-ethyl-α-isoamylmalonic ester is reacted with urea (in the presence of sodium ethoxide).

## Society and culture

On the night of August 28, 1951, the housekeeper of actor Robert Walker found him to be in an emotional state. She called Walker's psychiatrist who arrived and administered amobarbital for sedation. Walker was allegedly drinking prior to his emotional outburst, and it is believed the combination of amobarbital and alcohol resulted in a severe reaction. As a result, he passed out and stopped breathing, and all efforts to resuscitate him failed. Walker died at 32 years old.
The British actor and comedian Tony Hancock killed himself in Australia in 1968 using the drug in combination with alcohol.
Eli Lilly manufactured amobarbital under the brand name Amytal until it was discontinued in the 1980s and replaced largely by the benzodiazepine family of drugs. Amytal was also widely abused. Street names for amobarbital include "blues", "blue angels", "blue birds", "blue devils", and "blue heavens" due to their blue capsule.
`,
};
